Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 751 - 800 out of 3,729

Document Document Title
WO/2008/035239A1
The invention relates to phenyl derivatives of formula (I), their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.  
WO/2008/036652A2
The present invention is directed to amidino heterocyclic compounds of formula Ia and IIa which are modulators of indoleamine 2, 3 - dioxygenase (IDO), as well as compositions and pharmaceutical methods thereof.  
WO/2008/030570A1
Provided herein are processes for the preparation of compounds useful for the treatment, prevention or management of diseases associated with a nonsense mutation. More specifically, provided herein are processes for the synthesis of 1,2,...  
WO/2008/023783A1
[PROBLEMS] To provide a compound having an activity of suppressing an immune response and having reduced adverse side-effects and, therefore, useful in a chemotherapy for preventing or treating a wide variety of autoimmune diseases or ch...  
WO/2008/023157A1
A compound of formula (I): Formula (I) having M3 receptor- antagonist activity or having both muscarinic receptor antagonist and β2-agonist activity; a composition comprising such a compound; the use of such a compound in therapy (such ...  
WO/2008/021849A2
Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.  
WO/2008/016692A2
The invention provides compounds formula I, their preparation, and their use as pharmaceutically active immunosuppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activate...  
WO/2008/016139A1
An oleamide can emit fluorescence without largely deteriorating its biological activity by introducing a fluorescent group into the oleamide via a carbon chain, as shown in the formula (I). The fluorescent group (R) may be a dansyl group...  
WO/2008/007780A1
Disclosed is a pentadienamide derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof or the like. (I) wherein R1 represents a substituted or unsubstituted aryl or a substituted or unsubstituted aromatic h...  
WO/2007/144571A1
Novel crystalline forms of the compound (trans-4- {4-[({5-[(3,4-difluorophenyl)amino]- 1,3,4-oxadiazol-2-yl}carbonyl)amino]phenyl}cyclohexyl)acetic acid are provided, together with processes for the manufacture of such forms, pharmaceut...  
WO/2007/143822A1
This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I), and racemic and scalemic mixtures, diastereomers and enantiomers thereof: (I) or an N-...  
WO/2007/141545A1
Compounds of formula (I), or salts thereof, which inhibit acetyl CoA(acetyl coenzyme A):diacylglycerol acyltransferase (DGAT1) activity are provided, wherein, for example, R1 is optionally substituted phenyl or naphthyl; Ring A is select...  
WO/2007/138311A1
Compounds of formula (I), or salts thereof, which inhibit acetyl CoA(acetyl coenzyme A):diacylglycerol acyltransferase (DGAT1) activity are provided, wherein R1, R2 and R3 are each independently selected from hydrogen, fluoro, chloro, cy...  
WO/2007/138304A1
Compounds of formula (I), or salts thereof, which inhibit acetyl CoA(acetyl coenzyme A):diacylglycerol acyltransferase (DGAT1) activity are provided, wherein: n is 1, 2 or 3 and each R is independently selected from fluoro, chloro, cyano...  
WO/2007/138033A1
The present invention relates to novel oxadiazole derivatives of formula (1) having pharmacological activity, processes for their preparation, compositions containing them and their use in the treatment of neurological, psychiatric disor...  
WO/2007/136051A1
This invention provides an optical recording material, which can solve a problem of recording density in an optical recording medium, and an optical recording medium using the optical recording material. The optical recording material co...  
WO/2007/132307A1
The invention relates to compounds of formula (I) and to pharmaceutically acceptable salts, prodrugs, solvates or hydrates thereof; wherein B, D, E, R1, R2, R3, R4, R5, R8, m, n, p, q, r, s, t and u are as defined herein. This invention ...  
WO/2007/128137A1
A monomer of formula (I) may be used to prepare a poly(arylene ether) of formula (II) wherein k is 1 or 2, n is a non-zero number from 0 to 1, j is 0, 1 or 2, Q is O or S, L is a leaving group, Z is F or CI, Z' is F, CI or an organic gro...  
WO/2007/124024A2
The disclosed invention relates to a process for preparing 5-β-keto-1,2,4-oxadiazoles of formula (I), and conversion of 5-β-keto-1,2,4-oxadiazoles (I) into N-pyrazolyl amidoximes of the formula (II) through reaction with hydrazine. The...  
WO/2007/123225A1
[PROBLEMS] To provide a compound which can be used as a pharmaceutical agent, particularly an insulin secretion enhancer or a prophylactic/therapeutic agent for a disease associated with GPR40 such as diabetes. [MEANS FOR SOLVING PROBLEM...  
WO/2007/113634A1
The present invention relates to novel compounds representated by formula (I), where R, R1, R2, R3, X, Y, m, n are as defined.The present invention relates to compounds of the general formula I their derivatives, their analogs, their tau...  
WO/2007/104719A1
The present invention relates to novel diphenylurea derivatives of formula (I) useful as chloride channel blockers or BKCa channel modulators. In other aspects the invention relates to the use of these compounds in a method for therapy, ...  
WO/2007/098474A1
Compounds I and II that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.  
WO/2007/092638A1
Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.  
WO/2007/092190A2
The present invention relates to compounds which modulate the activity of the SlPl receptor, the use of these compounds for treating conditions associated with signaling through the SlPl receptor, and pharmaceutical compositions comprisi...  
WO/2007/091701A1
A discotic nematic material comprising a compound of R1-H1-Ar-H2-R wherein Ar represents a substituted or unsubstituted aromatic hydrocarbon ring; H1 and H2 represent an aromatic hetero ring; and R1 and R2 represent a substituent having ...  
WO/2007/085451A2
The present invention relates to polycyclic compounds of formula (I), processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.  
WO/2007/079931A1
The invention relates to substituted oxadiazole derivatives of general formula (I), in which X represents CH, CH2, CH=CH, CH2CH2, CH2CH=CH or CH2CH2CH2; R1 represents aryl or heteroaryl, which are respectively unsubstituted or mono- or p...  
WO/2007/074893A1
An oxadiazole derivative represented by the following general formula (G1) is synthesized and applied to the light emitting element, wherein Am is a substituent represented by a general formula (Am1), (Am2), or (Am3); each of α, β1, an...  
WO/2007/075598A2
The present invention is directed to N-hydroxyamidino compounds which are modulators of indoleamine 2,3-dioxygenase (IDO), as well as pharmaceutical compositions thereof and methods of use thereof relating to the treatment of cancer and ...  
WO/2007/071742A1
The invention relates to a process for preparing an optionally substituted 4-benzimidazol- 2-ylmethylamino)-benzamidine, characterised in that (a) an optionally correspondingly substituted diaminobenzene is condensed with 2 [4- (1,2,4-ox...  
WO/2007/071609A1
Compounds of formula I wherein X is O or S(=O)n; n is 0,1 or 2; R1 is optionally substituted alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, cycloalkyl, halocycloalkyl, cycloalkenyl, halocycloalkenyl, phenyl, hetaryl, pheny...  
WO/2007/069773A1
The present invention provides a novel modulator of the TRPV1-receptor function, comprising a compound of the formula; wherein ring A is an optionally substituted carbocycle or heterocycle, ring B is an optionally substituted benzene rin...  
WO/2007/068894A2
The invention relates to substituted diphenylethers, -amines, -sulfides, and -methanes as useful pharmaceutical compounds for treating respiratory- disorders, pharmaceutical compositions containing them, and processes for their preparation.  
WO/2007/067817A1
The present invention provides compounds having the structure of Formula (I), wherein R1 is optionally substituted lower alkyl, optionally substituted cycloaikyl, or optionally substituted aryl; R2 is hydrogen, carboxyalkyl, optionally s...  
WO/2007/067994A1
Disclosed herein are carbonyl compounds of having the structural formula: (I) or a salt, ester, or prodrug thereof, Methods and compositions are disclosed for treating disease states including, but not limited to cancers, autoimmune dise...  
WO/2007/065821A1
The present invention relates to compounds of formula (I) wherein R1, R2 and R3 are as defined herein and pharmaceutically acceptable salts thereof. The invention also relates to methods of using the compounds of formula (I) and pharmace...  
WO/2007/067993A1
Disclosed herein are compounds of formula I and methods used for treating disease states including, but not limited to cancers, autoimmune diseases, tissue damage, central nervous system disorders, neurodegenerative disorders, fibrosis, ...  
WO/2007/062773A1
Compounds of formula (I) are CRTH2 ligands, useful for treatment of inflammatory, autoimmune, respiratory or allergy disease: wherein R1 is hydrogen or methyl and R2 is optionally substituted cycloalkyl, or optionally substituted non-aro...  
WO/2007/060112A1
The present invention refers to O-acyl salicylic acid derivatives (I) bearing a NO donor moiety, a process for their preparation and pharmaceutical compositions containing them. (I) wherein : D is ONO2 or (A).  
WO/2007/056469A2
Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.  
WO/2007/048771A1
A compound of formula (I), wherein substituents are as given above, useful in the treatment of a disease mediated by the action of CCR3, in particular inflammatory or obstructive airway diseases.  
WO/2007/045366A1
The present application relates to new heterocyclic compounds, methods for preparing the same, their use for the treatment and/or prevention of diseases, and their use for producing medicaments for the treatment and/or prevention of dise...  
WO/2007/043400A1
Disclosed are: a novel compound having one or both of a xanthine oxidase inhibitory activity and an uric acid excretion promoting activity; a pharmaceutical composition comprising the compound as an active ingredient; use of the compound...  
WO/2007/043401A1
Disclosed are: a novel compound having a xanthine oxidase inhibitory activity and an uric acid excretion promoting activity; and a pharmaceutical composition comprising the compound as an active ingredient. The compound is a nitrogenated...  
WO/2007/037187A1
A sulfonamide derivative having DP receptor antagonistic activity; and a medicinal composition and a therapeutic agent for allergic diseases which each contains the compound as an active ingredient. The derivative is a compound represent...  
WO/2007/029793A1
Disclosed is an aryl heterocyclic derivative which can be commercially advantageously synthesized and safely used as a surely effective active ingredient for bactericides for agricultural and horticultural use. Also disclosed are a salt ...  
WO/2007/025718A1
The present invention relates to novel compounds which inhibit urokinase-plasminogen activator (uPA), have a high bioavailability and can be administered orally, and to their use as therapeutic active substances for the treatment of diso...  
WO/2007/022845A1
The invention relates to compounds of formula (1) and to the use thereof in organic electroluminescent devices. The compounds of formula (1) are used as host material or as a dopant in the emitting layer and/or as hole transport material...  
WO/2007/017414A1
Dicyanoalkane compounds of formula (I), wherein R1, R2, R3,R4 and A are defined as in the description, or the enantiomers or diastereomers or salts thereof are subject matter of the present invention. Further also processes and intermedi...  

Matches 751 - 800 out of 3,729